Table 2.
Mortality Associated with Respiratory Syncytial Virus Pneumonia in Adult Bone Marrow Transplant Recipients and Adults with Leukemia
| Mortality (%) |
||
|---|---|---|
| Therapya | BMT (n = 23) | Leukemia (n = 17) |
| Earlyb | 4/13 (31) | 0/8 (0) |
| Early (noncompliant) | — | 2/2 (100) |
| Early (6 h/day) | 1/1 (100) | — |
| Lateb | 5/5 (100) | 4/4 (100) |
| None | 4/4 (100) | 2/3 (66) |
BMT = bone marrow transplant.
a
Therapy consisted of aerosolized ribavirin (20 mg/mL for 18 h/day) and intravenous immunoglobulin (IV Ig; 500 mg/kg every other day). One patient received aerosolized ribavirin (60 mg/mL for 2 h every 8 h) and IV Ig.
b
Therapy was classified as “early” or “late” depending on whether it was initiated >24 h or <24 h prior to respiratory failure requiring mechanical ventilation, respectively.